Oncology News | pharmaphorum

News

Veraxa says delayed US listing is back on track

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

Kelonia's in vivo CAR-T data will feature at ASH

Kelonia only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but will report impressive results at ASH next month.

News

Torso of doctor with surgical gloves holding prescription pill bottle in one hand and multiple $100 bills in the other

Latest Medicare pricing cuts promise $12bn in savings

The CMS has revealed the prices for the second batch of 15 drugs going through Medicare's negotiation process, promising net savings of 44% on 2024.

News

NICE backs NHS use of Autolus' leukaemia CAR-T

Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

News

ADC specialist Solve raises $120m, and other biofinancings

Our round-up of biofinancings is led by a $120m round for ADC specialist Solve, with Aspen, Artios, Profluent, and Gate Bioscience also raising funds.

Veraxa says delayed US listing is back on track

FDA starts priority review of BeOne's Venclexta rival

Kelonia's in vivo CAR-T data will feature at ASH

Latest Medicare pricing cuts promise $12bn in savings

NICE backs NHS use of Autolus' leukaemia CAR-T

ADC specialist Solve raises $120m, and other biofinancings

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks